BMS is providing credits for 340B overcharges during Q3 2021 on one new NDC of its cancer drug Opdivo.

BMS Providing 340B Refunds on Cancer Drug Opdivo

Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report